Clinical Trials
29 trialsTAILORx
National Cancer Institute (NCI)
PIKALO-1
Eli Lilly and Company
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Eli Lilly and Company
Adjuvant WIDER
Novartis
Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
National Cancer Institute (NCI)
CAMBRIA-2
AstraZeneca
ELEGANT
Stemline Therapeutics, Inc.
CAMERAN
UNC Lineberger Comprehensive Cancer Center
A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer
Shandong Suncadia Medicine Co., Ltd.
BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder
University of Illinois at Chicago
LITESPARK-029
Merck Sharp & Dohme LLC
TREAT ctDNA
European Organisation for Research and Treatment of Cancer - EORTC
COMBINE-01
European Institute of Oncology
Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study
Fujian Cancer Hospital
CAMBRIA-1
AstraZeneca
POWER II
University of Virginia
GIM10-CONSENT
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Pfizer
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
Genentech, Inc.
DEBRA
NRG Oncology
PIKASSO-01
Eli Lilly and Company
PHACS
Institut Claudius Regaud
OXYTAM
Institut Claudius Regaud
MIRHO
Institut Claudius Regaud
ADEPT
Dana-Farber Cancer Institute
EMBER-4
Eli Lilly and Company
BabyTEARS
Dana-Farber Cancer Institute
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
Ellipses Pharma
MNEMOSYNE
Centre Oscar Lambret